Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design

Maurizio Averna, Alessio Farcomeni, Annarita Vestri, Francesco Violi, Daniele Pastori, Daniele Pastori, Daniele Pastori, Roberto Carnevale, Francesco Cipollone, Giovanni Targher, Andrea Lenzi, Francesco Angelico

Risultato della ricerca: Articlepeer review

4 Citazioni (Scopus)

Abstract

Type 2 diabetes mellitus (T2DM) is one of the most common causes of chronic kidney disease and kidney failure. It has been estimated that the annual decline of estimated glomerular filtration rate (eGFR) among patients with T2DM is approximately 2.0-2.5mL min(-1) y(-1). Cyclooxygenase-dependent eicosanoids, such as 11-dehydro-thromboxane (Tx)B2, are increased in T2DM patients and are potentially involved in the regulation of renal blood flow. Animal models showed that cyclooxygenase inhibitors, such as aspirin, are associated with improvements in renal plasma flow and eGFR values.
Lingua originaleEnglish
pagine (da-a)120-127
Numero di pagine8
RivistaAmerican Heart Journal
Volume189
Stato di pubblicazionePublished - 2017

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Entra nei temi di ricerca di 'Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design'. Insieme formano una fingerprint unica.

Cita questo